Peter Lynch fit · Growth at a reasonable price (GARP)
Is Apellis Pharmaceuticals, Inc. (APLS) a Peter Lynch Stock?
Strong GARP candidate - growth at a reasonable price.
81/100
CMixed signals
3/6 criteria passed
+8 sector-quality lift. Top-quintile within its sector on 4 of 5 quality metrics. Raw pillar score 73 → lifted to 81 before grade derivation.
Capped from A to C. Share count growing >5%/year - per-share growth eaten by dilution (kills Lynch's whole thesis) What are deal-breaker caps?
Peter Lynch's Criteria, Applied to APLS
PEG ≤ 1.0
key-
EPS CAGR ≥ 15%
key-
Revenue CAGR ≥ 10%
97.1%
Net margin > 0
12.1%
How APLS Scores on Other Strategies
Live Financial Snapshot
Market cap
$5.25B
P/E (TTM)
38.8x
ROIC (TTM)
18.11%
Gross margin
90.12%
Other Peter Lynch fit reports
Frequently Asked Questions
What is APLS's Peter Lynch fit score?
APLS scores 81/100 on our Peter Lynch fit engine - grade C. Strong GARP candidate - growth at a reasonable price.
Does Peter Lynch actually own APLS?
Our score is computed from financial fundamentals against Peter Lynch's published criteria. We don't claim that Peter Lynch personally owns or recommends APLS.
How often is this score updated?
APLS's Peter Lynch fit score is recomputed daily from the latest TTM financials. The page below shows when it was last refreshed.
Educational tool, not investment advice. Scores are computed from publicly-available financial data against published investing-strategy criteria. We do not claim that Peter Lynch personally owns or recommends APLS.